NewsRoom Articles - Page 113 of 214

ThursdayMay 12, 2022 12:59 pm

Study Discovers Mechanisms Behind Relapse After Treatment of MDD

A new study has discovered abnormalities in neural emotional regulation in individuals suffering from remitted major depressive disorder (MDD). The study’s findings highlight some neural mechanisms that may play a role in relapse. The author of the study, Rozemarijn S. van Kleef, stated that the interest in this role arose from the fact that depression recurring after remission was a huge issue on a societal as well as a personal level. A psychological therapist, van Kleef explained that it was crucial to gain more insight into the mechanisms underlying this recurrence, giving the examples of prior studies, which had found…

WednesdayMay 11, 2022 11:36 am

Researchers Develop Models to Better Understand Brain Cancer Metastasis

When cancer cells spread to the brain, they lead to the formation of brain metastases. Metastases are the primary cause of mortality and morbidity linked to cancer. Researchers at Instituto de Medicina Molecular have developed models to study brain metastases, which may help to better understand cancer and find new treatment approaches that can be modified to fit the needs of every patient. For their study, the researchers gathered brain metastases from patients with cancer that arose from tumors located in other organs. They used these cells to generate ailment models that mimicked the illness of every patient. The scientists…

WednesdayMay 11, 2022 11:15 am

Silo Pharma Inc. (SILO) Spotlight: Ketamine

Ketamine shows promise in treating Alzheimer’s Disease, Parkinson’s Disease as well as depression, suicide ideation and more In 2021, Silo Pharma (OTCQB: SILO) entered into a joint venture with Zylö Therapeutics to “explore the clinical development of ketamine using ZTI’s Z-pod (transdermal) technology.” This innovative technology allows Silo, an early-stage biopharmaceutical company, to develop a ketamine delivery system for those suffering dysphagia, a difficulty or complete inability to swallow.(1) Silo Pharma is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”). Over 80% of PD patients(2) and 75% of AD patients(3)…

WednesdayMay 11, 2022 10:30 am

Investor Event Turns Spotlight on Novel Brain Cancer Drug Candidate Global Trial Under Way by CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)

CNS Pharmaceuticals is developing a proprietary drug candidate that has the potential to deliver a novel solution for unmet medical needs in treating an incurable brain cancer CNS’s drug candidate is called Berubicin, a powerful anthracycline that appears to be the first such chemotherapy agent able to successfully cross the blood-brain barrier Berubicin dosing has begun in a potentially pivotal global trial that is recruiting glioblastoma multiforme (“GBM”) brain cancer patients The FDA has granted CNS fast-track authorization in regard to Berubicin’s development, and European countries’ drug regulatory bodies are also granting authorization to advance the trial process there An…

TuesdayMay 10, 2022 3:09 pm

Study Finds Service Dogs Help Individuals with PTSD

Post-traumatic stress disorder is a mental health disorder brought on by experiencing or witnessing a traumatic or terrifying event. This condition may last a few months or even years, with triggers unearthing traumatic memories and causing intense physical and emotional reactions. To help manage the condition’s symptoms, patients are sometimes assigned a buddy dog to be their companion during their daily activities. For a long time, patients with post-traumatic stress disorder have argued that a buddy dog helped better their lives. However the lack of scientific evidence made it hard to substantiate these claims — until now. A new study…

MondayMay 09, 2022 2:02 pm

U.S. Army Sued Over Discharging Soldiers with Substance-Abuse Issues

The U.S. Army is being sued for violating the Constitution as well as its own regulations and veterans’ rights by failing to give soldiers with drug and alcohol use disorders honorable discharges, which would have qualified them for federal benefits. Army Secretary Christine Wormuth is being sued by Mark Stevenson, an army veteran, in federal court. Stevenson seeks to compel the military to upgrade his discharge status as well as those of other veterans who weren’t honorably discharged due to misconduct associated with their substance abuse disorders. Stevenson enlisted in the U.S. Army in 1977, revealing that he developed problems…

FridayMay 06, 2022 11:54 am

Study Finds Strong Link Between Hormone Drug, Growth of Brain Tumors

A new study has found that a drug that is commonly used to hormonally treat conditions such as prostate cancer, early puberty and excessive hair growth may be linked to a heightened risk of meningioma. The study was carried out by researchers at the University of Bristol who collaborated with researchers at the National University of Singapore and the University of Cambridge. The findings were published in “Scientific Reports.” Meningioma is a common type of brain tumor that is typically benign and slow growing. These tumors are known to trigger disability by squeezing or compressing the adjacent vessels and nerves…

FridayMay 06, 2022 9:00 am

Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial

Cybin has selected Clinilabs Drug Development Corporation as CRO for its Phase 1/2a clinical trial evaluating CYB003 for treating major depressive disorder (“MDD”) MDD impacts more than 264 million people worldwide, is a leading cause of mental disability worldwide Preclinical studies show CYB003 may have significant advantages over classic psilocybin In a significant step forward in the study of alternative treatments for major depressive disorder, Cybin (NEO: CYBN) (NYSE American: CYBN) is moving forward in its phase 1/2a clinical trial of its proprietary deuterated psilocybin, CYB003 (https://ibn.fm/VTjoI). Based on previous research, CYB003 has the potential to effectively treat MDD with significant…

ThursdayMay 05, 2022 12:52 pm

New Study Sheds Light on Inflammation Linked to COVID-19

A new study has provided new insights into why the SARS-CoV-2 virus, which is known to cause COVID-19, can sometimes fuels inflammation, which in turn causes serious illness. This research was led by scientists at Boston Children’s Hospital and Harvard Medical School. Its findings were published in the “Nature” journal. The researchers also discovered that the SARS-CoV-2 virus infects and kills specific cells in the immune system in the lungs and the blood. The elimination of these alarms is what triggers the immune system. In a news release, Professor Judith Lieberman, one of the leaders of the study, stated that…

WednesdayMay 04, 2022 3:17 pm

Study Says Antidepressants Don’t Meaningfully Improve Depressed People’s Well-Being

Depression is a mood disorder that causes an individual to experience feelings of sadness that persist for longer than a fortnight, which impacts their ability to carry out daily activities. A recently conducted study has found that individuals who use antidepressants to manage their depression observe no improvements in their overall mental and physical well-being in comparison to those who don’t take antidepressants. Figures from the National Institute of Mental Health show that more than 20 million grownups in America have suffered at least one depressive episode in the course of their lives. The study’s findings were published in “PLOS…